bioRxivCell BiologyPreprint
JMJD5 regulates metabolism by hydroxylating ISY1, and regulating the Arginine Methyltransferase PRMT6
Zaid KhaniD, Chartinun Chutoe, Jair Gonzalez Marques JúnioriD, Edward J. JarmaniD, Andreea Gradinaru, Anthony TumberiD, Eidarus Salah, Martin Lee, Haya Al Siyabi, Philippe Emmanuel GautieriD, Chinmayi PednekariD, Ann P. WheeleriD, Christopher J. SchofieldiD, Luke BoulteriD, Alexander von Kriegsheim
Abstract
2-Oxoglutarate-dependent dioxygenases (2OGDDs) employ molecular oxygen, 2-oxoglutarate, and ferrous iron to catalyse two-ectron oxidations. This dependency enables some 2OGDD to act as sensors of cellular metabolic states, driving crucial functions when oxygen or metabolic homeostasis is perturbed, including adaptation to low oxygen, epigenetic control of gene transcription, and the reshaping of metabolic pathways. Jumonji-C (JmjC) domain-containing protein 5 (JMJD5), a 2OGDD that regulates epigenetic marks, is essential for DNA damage repair and is a key regulator of cell metabolism. Notably, JMJD5 is often reduced in hepatocellular carcinoma, correlating with poor overall survival. Despite its biological significance, the molecular functions of JMJD5 remain unresolved, and its physiological targets are elusive. Here, we identify and characterise a novel signalling pathway where JMJD5 hydroxylates an arginine residue on the protein ISY1. This modification enables ISY1 to bind to and reduce the activity of Protein Arginine N-methyltransferase 6 (PRMT6). Significantly, the inactivation of PRMT6 rescues the majority of the molecular phenotype driven by JMJD5 loss, establishing the JMJD5-ISY1-PRMT6 pathway as a principal executor of JMJD5s enzymatic function. In a genetically engineered murine liver cancer model, JMJD5 loss suppressed tumour growth and rewired one-carbon, amino acid, and lipid metabolism, recapitulating the network-level changes observed in human HCC cells. This signalling pathway clarifies existing controversies regarding JMJD5s function and identifies PRMT6 as a potential therapeutic target for treating cancers that lack JMJD5.
- organism: mouse
- research focus: cancer & tumor microenvironment
- research focus: metabolism & bioenergetics
- research focus: cell type annotation
- approach: experimental assay
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Inactivation of a protein hydroxylase complex impairs replication fork restart in cancer and neurodevelopmental disorders
Tristan J. Kennedy, Sally C. Fletcher, … Mathew L. Coleman·bioRxiv·Nov 22, 2025
- The UTX Tumor Suppressor Directly Senses Oxygen to Control Chromatin and Cell Fate
A. Chakraborty, T. Laukka, … W. G. Kaelin·bioRxiv·Jan 3, 2019
- Protein arginine methyltransferase 5 promotes metastasis via enhancing EGFR transcription and modulating AKT1 activation by methylation
L. Huang, X.-O. Zhang, … J. Q. Wu·bioRxiv·Aug 12, 2020
- Transcriptomic and proteomic regulation through abundant, dynamic, and independent arginine methylation by Type I and Type II PRMTs
Maxim I. Maron, Stephanie M. Lehman, … David Shechter·iSciencePeer-reviewed·Aug 11, 2021
- PRMT5 inhibition induces a histone methylation switch that drives chromatin plasticity, drug resistance, and metastatic progression
Colin E Fowler, Natalie A. O’Hearn, … Jacqueline A. Lees·bioRxiv·Oct 10, 2026
- PRMT5 activity sustains histone production to maintain genome integrity
Jacob S. Roth, Joseph D. DeAngelo, … David Shechter·bioRxiv·Jul 3, 2025